Wegovy Now Available as Oral Tablets in the UK

Weight loss drug Wegovy to be available – The UK has approved the first tablet version of Wegovy, a widely used weight-loss medication, making it accessible to patients through prescription. This marks a significant milestone as the Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral form, which is expected to streamline treatment for many individuals. The development offers an alternative to the current injectable formulation, which requires weekly administration and refrigeration. Novo Nordisk, the manufacturer, highlights that the daily pill may provide a more user-friendly option for patients who prefer oral medications over injections.

Convenience and Accessibility

The new tablet form of semaglutide, the active ingredient in Wegovy, is designed to simplify the treatment process. Unlike the injectable version, which demands careful handling and storage, the oral tablets can be taken without refrigeration, easing logistics for patients. The transition from injections to pills is particularly beneficial for those who struggle with needle phobia or find it difficult to maintain a consistent regimen. Novo Nordisk emphasizes that the pill’s simplicity could enhance adherence to the medication, which is crucial for long-term success in managing weight.

Cost and Availability

While the NHS has not yet included Wegovy in its funding list, the medication is anticipated to be available through private prescribing services in the coming weeks. Several pharmacies, including both high street and online retailers, are preparing to offer the tablets, expanding access for individuals seeking alternative weight-loss options. The pricing in the UK remains undisclosed, but in the United States, the manufacturer lists the starting dose of 1.5 mg at $149 (£110) per month. This cost may influence patient choices, especially as other pharmaceutical companies are developing similar drugs to compete in the market.

How the Medication Works

Wegovy’s oral tablets function by delivering semaglutide, a drug that mimics the effects of GLP-1, a hormone naturally produced in the body to regulate appetite and digestion. By activating this hormone, the tablets help reduce hunger and prolong the feeling of fullness, supporting weight management. This mechanism is similar to the injectable form, which has been used for several years. However, the tablet version may offer greater flexibility, allowing patients to integrate it into their daily routines more easily.

Expert Perspectives and Future Steps

“The approval of the oral tablet form is a significant development,” said Olivier Picard, Chair of the National Pharmacy Association. “It could help patients who are unable or unwilling to use the injectable version, while also potentially reducing long-term treatment costs.”

Picard’s remarks underscore the potential impact of the tablet form on patient care. However, the National Institute for Health and Care Excellence (NICE) has not yet received a formal request from Novo Nordisk to evaluate its inclusion in the NHS. Despite this, the agency is engaged in ongoing discussions with the company to determine whether the medication should be recommended for public funding. Until a decision is made, the focus remains on private availability and its role in the broader weight-loss market.

Dosing Guidelines and Transition Options

The MHRA has outlined a dosing schedule for the tablet version, starting at 1.5 mg daily and gradually increasing to 4 mg, 9 mg, and 25 mg over a minimum of one month at each stage. This gradual escalation is intended to minimize side effects while optimizing therapeutic outcomes. Patients currently using the weekly injectable form of semaglutide (2.4 mg) can seamlessly transition to the daily tablet, as the dosing levels align in effectiveness. The flexibility of the tablet form may also encourage broader adoption, particularly among those who find the injectable method challenging.

Long-Term Considerations and Patient Advice

While the medication is effective, its benefits require consistent use over several months. Experts caution that weight may rebound once treatment is discontinued, emphasizing the need for sustained effort. Patients are advised to complement the medication with a balanced diet and regular physical activity, as these lifestyle factors are essential for maintaining results. GLP-1 drugs like Wegovy are not intended for short-term or cosmetic weight loss, yet they are often used for quick fixes, such as preparing for seasonal events.

Side Effects and Safety

Common side effects of Wegovy tablets include gastrointestinal issues such as nausea, diarrhea, constipation, and vomiting. These symptoms are typically mild and subside as the body adjusts to the medication. Clinical trials have confirmed the safety of the tablet form, though they also highlight the importance of monitoring patients for potential adverse reactions. The MHRA’s approval ensures that the medication meets rigorous standards, but ongoing research will further refine its usage and benefits.

Prevalence of Obesity in the UK

Approximately one-third of UK adults—over 16 million people—are classified as obese, according to recent data. This statistic underscores the demand for effective weight-management solutions. The introduction of the tablet form of Wegovy is expected to address this need by offering a more convenient option for a wider patient population. As the medication becomes more accessible, healthcare providers may see an increase in prescriptions, particularly among individuals who previously avoided the injectable version due to logistical or personal preferences.

Novo Nordisk’s tablet version of Wegovy represents a pivotal shift in the treatment landscape for obesity. While the NHS decision remains pending, the availability of the medication through private channels signals a growing emphasis on personalized healthcare. As more patients explore this alternative, the pharmaceutical industry is likely to see increased competition, further driving innovation in weight-loss therapies. For now, the focus is on ensuring that the pill form is properly integrated into existing treatment protocols, with a clear understanding of its role in both short-term and long-term weight management strategies.